With strong demand for ophthalmology treatments, the eye drug market has become a golden circuit

"Pharmaceutical Network Market Analysis" Recently, the National Health and Safety Commission held a regular press conference, and released the "China Eye Health White Book", which is the first domestic white book on eye health.
the results of the survey, the overall myopia rate among children and adolescents nationwide in 2018 was 53.6%.
6-year-olds are 14.5 per cent, primary school students 36.0 per cent, junior high school students 71.6 per cent and senior high school students 81.0 per cent.
demand for ophthalmology treatment can be seen from the data, the rate of myopia among children and adolescents has been more than half, and myopia among children and adolescents has become the main cause of vision impairment in China.
, in recent years, China's youth myopia rate continues to rank among the forefront of the world.
600 million people in China are nears sighted, according to a 2018 World Health Organization study.
, according to the 2019 National Visual Health Report of the China Health Development Research Center at Peking University, China's near-sighted population will reach 700 million by 2020, with a prevalence rate of nearly 50%.
Industry analysts believe that in such a large base, coupled with advances in communications and mobile Internet technology, more and more people, including teenagers, will become heavy mobile phone users, and long-term close-up overuse of electronic products, will continue to increase the prevalence of myopia, ingesting a huge ophthalmology business market.
In addition, with China's deepening aging, increased intensity of work, lifestyle changes, cataracts, glare, dry eyes, cornealitis and other eye diseases rate increased year by year, ophthalmology treatment demand will increase sharply, the ophthalmology market will usher in further rapid growth.
market will continue to grow rapidly at present, there are two dimensions of growth momentum in the ophthalmology sector: first, "demographic dividend plus increased penetration."
cataract surgery, glaucosis, under-eye disease and other fields in ophthalmology treatment have certain therapeutic necessities, while regressive surgery and visual light have certain consumption properties.
followed by "eye health attention to increased consumption upgrade."
health includes the full life cycle, medical services, ophthalmology supplies and ophthalmology drugs and other fields, wide coverage, treatment, drug demand is huge.
experts believe that in such a sustained growth momentum, the ophthalmology market will become one of the more prominent segments of the pharmaceutical industry.
expected that by 2021, the size of the domestic ophthalmology market may reach 159.4 billion yuan, the compound annual growth rate is expected to maintain at 13.9%.
note that while the market continues to grow, it will also become a gold track for many pharmaceutical companies.
, at the same time that the domestic ophthalmology market is expanding, ophthalmology enterprises have already begun to accelerate the market layout to compete for market share.
such as Eyre Ophthalmology has been playing an important role in the development process, in addition, De-Visual Jia, Shima ophthalmology and so on are also accelerating to seize the share of the ophthalmology market.
according to incomplete statistics, Eyre Ophthalmology has announced the acquisition of a total of 14 ophthalmology hospitals in Foshan, Qingyuan, Dongguan, Binzhou, Huzhou, Taiyuan and other places since 2017.
the first half of 2019, Eyre Ophthalmology once again perfected the hierarchical chain system, acquiring or building 13 hospitals and 9 outpatient clinics or clinics, respectively, Xiangtan Ren and Pu'er Eyre.
According to Eyre Ophthalmology's plan, by 2020, the company plans to set up 200 municipal hospitals, 1000 county-level hospitals or outpatient clinics, outpatient volume reached 10 million, the chain of hospitals to open a heart to the third and fourth-tier cities to sink.
,000-year-old Shima Ophthalmology, which previously acquired Kunming Eye Hospital and Shanghai-shanghai Vision Medical, has begun deploying the Yangtze River Delta region.
plans of the founder of Hima Ophthalmology to establish Hima Eye Hospital in six to ten cities over the next three years.
conclusion, the increase in the heat of the ophthalmology gold track is already evident, and the future is expected to be the birth of large-cap companies and fast-growing white horse companies.
industry suggests focusing on traditional ophthalmology White Horse Eyre Ophthalmology, Opcon Vision, Xingqi Eye Medicine, Bohai Health, Aibo Medical and other companies with hard-core capabilities.